

## Technology Appraisal Committee Meeting (Committee [A])

**Minutes:** Confirmed

**Date and Time:** 16<sup>th</sup> August 2016, 10am – 5pm

**Venue:** NICE London Offices  
Prince of Wales Suite  
10 Spring Garden  
SW1A 2BU

<b>Present:</b>	1. Chair Dr Jane Adam	Present for all notes
	2. <b>Professor John Watkins</b>	Present for all notes
	3. Dr Graham Ash	Present for all notes
	4. Dr Ian Bernstein	Present for all notes
	5. Mr Adrian Griffin	Present for notes 1 to 16
	6. Dr Rachel Hobson	Present for all notes
	7. Professor John McMurray	Present for all notes
	8. Dr Mohit Misra	Present for all notes
	9. Ms Pamela Rees	Present for all notes
	10. Dr Paul Robinson	Present for notes 1 to 16
	11. Ms Ellen Rule	Present for all notes
	12. Mr Stephen Sharpe	Present for all notes
	13. Dr Brian Shine	Present for all notes
	14. Mr David Thomson	Present for all notes
	15. Professor Olivia Wu	Present for all notes
	16. Dr Nerys Woolacott	Present for all notes
	17. Rita Faria	Present for all notes

### In attendance:

Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
<b>Liv Gualda</b>	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Marcia Miller	Technology Administrator, National Institute for Health and Care Excellence	Present for all notes
Helen Tucker	Technical Analyst, National Institute for Health and Care	Present for notes 1 to 16

## Excellence

Eleanor Donegan	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 1 to 16
Carl Prescott	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 17 to 28
Joanna Richardson	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 17 to 28

## Evidence review group

Rachid Rafia	School of Health Related Research	Present for notes notes 1 to 13
Sarah Davis	School of Health Related Research	Present for notes 1 to 13
Abdullah Pandor	School of Health Related Research	
<b>Norman Waugh</b>	University of warwick	Present for notes 1 to 13
Ewen Cummings	University of Warwick	Present for notes 1 to 13
<b><u>Clinical Experts</u></b>		Present for notes 1 to 13
<b>Dr Andrew Mcmillan</b>	<b>CONSULTANT HAEMATOLOGIST nominated by Royal College of Physicians</b>	Present for notes 1 to 13
<b>Dr John Gribben</b>	Professor of Medical Oncology, nominated by Roche	Present for notes 1 to 13
Dr Roger Gadsby	<b>Honorary Associate Clinical Professor nominatd by Janssen</b>	Present for notes 16 to 25
Dr Michael Feher	<b>CONSULTANT IN CLINICAL PHARMACOLOGY &amp; DIABETES</b>	Present for notes 16 to 25
<b><u>Patients Experts</u></b>		
<b>Katharine Robinson</b>	Patient expert nominated by Lymphoma Association	Present for notes 1 to 13
Ruth Waxman	Patient expert nominated by Diabetes UK	Present for notes 16 to 25

## Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of **Obinutuzumab with bendamustine for treating rituximab-refractory follicular lymphoma [ID841]**
2. The Chair informed the Committee of the non-public observers at this meeting: Chloe Kastoryano and Ria Skelton.
3. Apologies were received from Dr Jeremy Braybrooke, Dr Justin Daniels, Dr Andrew England, Dr Anne McCune, Mrs Sarah Parry and Professor Iain Squire

## Notes from the last meeting

4. Minutes of the last meeting were agreed

## Appraisal of **Obinutuzumab with bendamustine for treating rituximab-refractory follicular lymphoma [ID841]**

### Part 1 – Open session

5. The Chair welcomed the invited experts: Dr John Gribben, Dr Andrew McMillan, Katharine Robinson to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Roche to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
  - 7.1. **Dr Jane Adam, Professor John Watkins, Dr Graham Ash, Dr Ian Bernstein, Mr Adrian Griffin, Dr Rachel Hobson, Professor John McMurray Dr Mohit Misra, Ms Pamela Rees, Dr Paul Robinson, Ms Ellen Rule, Mr Stephen Sharp, Dr Brian Shine, Mr David Thomson, Professor Olivia Wu, Dr Nerys Woolacott and Rita Faria** all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of **Obinutuzumab with bendamustine for treating rituximab-refractory follicular lymphoma**
8. The Chair asked all NICE Staff to declare any relevant interests.

All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of **Obinutuzumab with bendamustine for treating rituximab-refractory follicular lymphoma**

9. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

Rachid Rafia, Sarah Davis, Abdullah Pandor and Katharine Robinson all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of **Obinutuzumab with bendamustine for treating rituximab-refractory follicular lymphoma**.

- 9.1. Dr John Gribben declared a personal non-specific financial interest as he has received honoraria for advisory boards and speaking for Roche, he has no personal financial interest to declare.  
9.1.1. It was agreed that this declaration would not prevent Dr John Gribben from participating in this section of the meeting.
- 9.2. Dr Andrew McMillan declared a personal non-specific financial interest as he has received honoraria from Roche and NAPP for Advisory boards, speaking at Satellite symposia and received sponsorship to attend International meetings.  
9.2.1. It was agreed that this declaration would not prevent Dr Andrew McMillan from participating in this section of the meeting.
10. The Chair introduced the lead team, Professor John Watkin, Mr David Thomson and Dr Mohit Misra who gave presentations on the clinical effectiveness and cost effectiveness of **Obinutuzumab with bendamustine for treating rituximab-refractory follicular lymphoma**.
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.
15. The Committee continued to discuss the clinical and cost effectiveness of **Obinutuzumab with bendamustine for treating rituximab-refractory follicular lymphoma**

16. The Committee instructed the technical team to prepare the **Appraisal Consultation Document (ACD)** in line with their decisions.

## Appraisal of Dapagliflozin in triple therapy regimens for treating type 2 diabetes

### Part 1 – Open session

17. The Chair welcomed the invited experts: Ewen Cummings, Dr Roger Gadsby, Dr Michael Feher, Norman Waugh and Ruth Waxman to the meeting and they introduced themselves to the Committee.
18. The Chair welcomed company representatives from Roche to the meeting.
19. The Chair asked all Committee members to declare any relevant interests
  - 19.1. **Dr Jane Adam, Dr John Watkins, Dr Graham Ash, Dr Ian Bernstein Professor John McMurray, Dr Mohit Misra, Ms Pamela Rees, Dr Paul Robinson, Ms Ellen Rule, Mr Stephen Sharpe, Dr Brian Shine, Mr David Thomson, Professor Olivia Wu, Dr Nerys Woolacott and Rita Faria** all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of **Appraisal of Dapagliflozin in triple therapy regimens for treating type 2 diabetes**
  - 19.2. **Dr Rachel Hobson** declared a non-personal specific financial interest as she participated in 2 advisory boards for Janssen in March and June 2015 about canagliflozin.
    - 9.2.1 It was agreed that this declaration would not prevent Dr Rachel Hobson from participating in this section of the meeting.
  - 19.3. **Mr Adrian Griffin was absent as Janssen the comparator company for the appraisal is owned by his employer Johnson and Johnson.**
  - 19.4. **Dr Paul Robinson was absent as the comparator drug staglitin is made by his employer Merck Sharpe and Dohme.**
20. The Chair asked all NICE Staff to declare any relevant interests.
  - 20.1. **All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Appraisal of Dapagliflozin in triple therapy regimens for treating type 2 diabetes.**
21. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

- 21.1. Ewen Cummings, Norman Waugh and Ruth Waxman all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of **Dapagliflozin in triple therapy regimens for treating type 2 diabetes.**
- 21.2. Dr Michael Feher declared a personal non-specific financial interest as he has sat on Advisory boards for Novo Nordisk, Sanofi, MSD and Eli Lilly
- 21.2.1. It was agreed that this declaration would not prevent Dr Michael Feher from participating in this section of the meeting
- 21.3. Dr Roger Gadsby declared a personal non specific financial interest as he has received payment for advisory work from Janssen and Eli Lilly in the past 2 years
- 21.3.1. It was agreed that this declaration would not prevent Dr Roger Gadsby from participating in this section of the meeting
22. The Chair introduced the lead team, Dr Mohit Misra, Pamela Rees and Mohit and Dr Oliva Wu who gave presentations on the clinical effectiveness and cost effectiveness of **Dapagliflozin in triple therapy regimens for treating type 2 diabetes.**
23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
24. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

26. Discussion on confidential information continued. This information was supplied by the company.
27. The Committee continued to discuss the clinical and cost effectiveness of **Dapagliflozin in triple therapy regimens for treating type 2 diabetes.**
28. The Committee instructed the technical team to prepare the **Final Appraisal Determination (FAD)** in line with their decisions.

## **Date, time and venue of the next meeting**

29. Tuesday 20<sup>th</sup> September 2016 at 10am, Prospero House, 241 Borough High Street, SE1 IGB.